A-Level Capital

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Yet Analytics operates a comprehensive data analytics platform for large enterprises. It collects data from diverse sources like web and mobile apps, wearables, IoT devices, and VR/AR systems to identify employee behavior trends and improve operational outcomes. Founded in 2014, it's headquartered in Baltimore, Maryland.

Sonavex develops imaging technologies for vascular and surgical care, employing ultrasound to detect postoperative blood clots at the point of care and to measure intravascular flow metrics for timely decision making. It also develops bioresorbable, echogenic devices to mark at-risk vessels and to collect data on arteriovenous fistula flow, diameter, and depth at dialysis clinics to assess maturation and anticipate future complications. Based in Baltimore, Maryland, Sonavex focuses on delivering data-driven visualization of vessel health to improve surgical and dialysis patient outcomes.